Our designer molecule HY-133 is on TV!
How can prevention and innovation contribute to patient satefy in the future?
In the NDR report, our cooperation partners at Greifswald University Medicine, led by Karsten Becker, explain how innovative phage endolysins could be used in hospitals in future to combat the common sepsis pathogen Stapylococcus aureus. This form of prophylaxis could make a difference in the future, for example to prevent post-operative infections or sepsis. We at HYpharm GmbH are contributing to this important fight without antibiotics against multi-resistant bacteria with innovative phage endolysins.
Because Time to Act is Now!